Search the Newsreel

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)

Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share …

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 15,000,000 American Depositary Shares (ADSs) in Autolus Therapeutics plc (AUTL), representing 5.64% of the outstanding ADSs. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Tapestry Inc. (TPR) PT Raised to $185 at Bernstein SocGen Group

Bernstein SocGen Group analyst Aneesha Sherman has raised the price target for Tapestry Inc. (TPR) to $185. The article is a premium-only piece, requiring a subscription to StreetInsider.com for full access.

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating

Oppenheimer has revised its price target for Abeona Therapeutics (ABEO) to $21 from $22, while reiterating an Outperform rating on the stock. This adjustment comes after Abeona Therapeutics' shares fell following a Q2 earnings miss. The article also provides a company profile, recent news, …

Form 8K Quince Therapeutics Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Quince Therapeutics Inc. on August 14. The financial document is brief and focuses solely on this specific filing for the mentioned date. It appears to be a standard notification without extensive details provided …

Tapestry Crushed Earnings but the Stock Plunged: Buy, Sell, or Hold Now?

Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake

Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have collectively reported a beneficial ownership stake of 7.06% in Hemab Therapeutics Holdings, Inc. (COAG). This ownership comprises 3,298,236 shares of common stock, acquired solely for investment purposes on behalf of their respective funds. …

Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Equities Analysts Offer Predictions for CADL FY2028 Earnings

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans

Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Brokers Offer Predictions for RAPP Q1 Earnings

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83

Analysts have revised down their revenue estimates for LENZ Therapeutics, Inc. for 2026 to US$17.0m, a significant 21% decline, despite beating recent revenue estimates. Although loss estimates were reduced, the consensus price target for LENZ Therapeutics was cut by 16% to US$26.83, reflecting pessimism …

Equities Analysts Set Expectations for TCRX FY2026 Earnings

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …

Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026

Quince Therapeutics announced a net loss of $75.5 million for Q2 2026, with $116 million in cash, cash equivalents, and investments as of June 30, 2026. The company completed a $115 million private placement concurrent with its acquisition of Orphai and initiated a Phase …

Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Autolus Therapeutics (NASDAQ:AUTL) recently released strong quarterly results, with revenues exceeding expectations and statutory losses coming in lower than forecast. Following these results, analysts have upgraded their revenue and loss per share estimates for 2026, indicating increased optimism for the company's future performance. Despite …

Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026

Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 7,999,025 Class A ordinary shares, representing a 9.74% stake in MoonLake Immunotherapeutics (MLTX). This ownership includes 1,000,000 Pre-Funded Warrants, …

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Kyverna Therapeutics (NASDAQ:KYTX) to a loss of $0.66 per share, an improvement from its previous forecast of a $0.78 loss. The firm maintained a "Buy" rating and a $25.00 price target for the stock. …

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …

H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35

H.C. Wainwright has reiterated its Buy rating for MiNK Therapeutics (INKT.US), maintaining a price target of $35. This indicates the firm's continued positive outlook on the company's stock performance.

HC Wainwright Has Positive Estimate for MAZE Q3 Earnings